Previous close | 0.1700 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 2.50 |
Expiry date | 2024-07-19 |
Day's range | 0.0500 - 0.1700 |
Contract range | N/A |
Volume | |
Open interest | 15 |
GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent’s Contract Development and Manufacturing Organization (CDMO), has clin
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard of care for opioid overdose reversal in a community settingNew topline survey findings reinforce the need for continued education on naloxone GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is highlighting its ongoing efforts to combat the opioid epidemic in the U.S., including topline results from its new